Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Applicability of 3D Histoculture Drug Response Assay(3D-HDRA) in Patients With Primary Liver Cancer: A Randomized Controlled Trial

NCT05701436 is registered in ClinicalTrials.gov with Zhujiang Hospital as lead sponsor.

NCT NCT05701436
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05701436 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Applicability of 3D Histoculture Drug Response Assay(3D-HDRA) in Patients With Primary Liver Cancer: A Randomized Controlled Trial
Lead sponsor
Zhujiang Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
September 1, 2022
Completion date
March 1, 2026
Enrollment
144 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

liver, cancer of, primary resectable